CN Patent
CN102118968A — 新的三环化合物
Assigned to AbbVie Inc · Expires 2011-07-06 · 15y expired
What this patent protects
本发明提供了式(I)的化合物,其药用可接受的盐,前药,生物活性代谢产物,立体异构体和异构体,其中变量在文中进行定义。本发明的化合物可用于治疗免疫和肿瘤状况。
USPTO Abstract
本发明提供了式(I)的化合物,其药用可接受的盐,前药,生物活性代谢产物,立体异构体和异构体,其中变量在文中进行定义。本发明的化合物可用于治疗免疫和肿瘤状况。
Drugs covered by this patent
- Rinvoq (upadacitinib) · AbbVie Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.